Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Scientific Reports
|
March 6, 2023
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub, et al.
Journal for Immunotherapy of Cancer
|
April 18, 2023
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Olaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Blood
|
May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Emanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
The Lancet. Oncology
|
July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Justin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
Lancet (London, England)
|
May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Blood
|
December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
Andrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Lancet (London, England)
|
May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
The Lancet. Haematology
|
November 3, 2023
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Martine E D Chamuleau, Frank Stenner, Dana A Chitu, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Scientific Reports
|
March 6, 2023
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub, et al.
Journal for Immunotherapy of Cancer
|
April 18, 2023
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Olaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Blood
|
May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Emanuele Zucca, Stephanie Rondeau, Anna Vanazzi, et al.
The Lancet. Oncology
|
July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Justin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
Lancet (London, England)
|
May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Blood
|
December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
Andrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Lancet (London, England)
|
May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
The Lancet. Haematology
|
November 3, 2023
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Martine E D Chamuleau, Frank Stenner, Dana A Chitu, et al.
Page
of 11